Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|
Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|---|---|---|---|---|---|---|---|
Q4 2024 | 95 | $9.36B | +$291M | -$239M | +$52M | INCY, ONC, ACAD, MDGL, SMMT | 13F-HR | 2/14/2025, 04:12 PM |
Q3 2024 | 93 | $9.65B | +$239M | -$134M | +$105M | BGNE, INCY, ACAD, SMMT, MDGL | 13F-HR | 11/14/2024, 04:07 PM |
Q2 2024 | 95 | $7.83B | +$925M | -$626M | +$300M | INCY, BGNE, ACAD, MDGL, RVMD | 13F-HR | 8/14/2024, 04:05 PM |
Q1 2024 | 87 | $7.97B | +$382M | -$511M | -$129M | INCY, BGNE, ACAD, MDGL, RYTM | 13F-HR | 5/15/2024, 04:37 PM |
Q4 2023 | 84 | $8.79B | +$625M | -$10.3B | -$9.69B | INCY, BGNE, ACAD, MDGL, RYTM | 13F-HR | 2/14/2024, 05:12 PM |
Q3 2023 | 101 | $17.4B | +$187M | -$322M | -$134M | SGEN, BGNE, INCY, ACAD, BMRN | 13F-HR | 11/14/2023, 04:25 PM |
Q2 2023 | 107 | $17.3B | +$437M | -$522M | -$85.6M | SGEN, INCY, BGNE, ACAD, MDGL | 13F-HR | 8/14/2023, 04:13 PM |
Q1 2023 | 105 | $18.4B | +$255M | -$1.25B | -$996M | SGEN, INCY, BGNE, ACAD, MDGL | 13F-HR | 5/15/2023, 04:04 PM |
Q4 2022 | 113 | $16.7B | +$272M | -$571M | -$298M | SGEN, INCY, BGNE, BMRN, ACAD | 13F-HR | 2/14/2023, 04:06 PM |
Q3 2022 | 115 | $15.3B | +$270M | -$589M | -$319M | SGEN, INCY, BGNE, ACAD, BMRN | 13F-HR | 11/14/2022, 04:06 PM |
Q2 2022 | 117 | $17.6B | +$252M | -$199M | +$53.1M | SGEN, INCY, BGNE, BMRN, ACAD | 13F-HR | 8/15/2022, 04:56 PM |
Q1 2022 | 118 | $17.4B | +$347M | -$107M | +$240M | SGEN, INCY, BGNE, ACAD, BMRN | 13F-HR | 5/16/2022, 04:05 PM |
Q4 2021 | 121 | $20.6B | +$386M | -$191M | +$195M | SGEN, BGNE, INCY, KOD, ACAD | 13F-HR | 2/14/2022, 04:09 PM |
Q3 2021 | 122 | $22.8B | +$594M | -$307M | +$287M | SGEN, BGNE, INCY, KOD, ASND | 13F-HR | 11/15/2021, 03:58 PM |
Q2 2021 | 120 | $22.8B | +$488M | -$972M | -$485M | SGEN, BGNE, INCY, KOD, ACAD | 13F-HR | 8/16/2021, 04:11 PM |
Q1 2021 | 126 | $23.1B | +$741M | -$871M | -$130M | SGEN, BGNE, INCY, KOD, ACAD | 13F-HR | 5/17/2021, 04:03 PM |
Q4 2020 | 126 | $26.5B | +$1.16B | -$1.25B | -$95.5M | SGEN, BGNE, INCY, ACAD, KOD | 13F-HR | 2/16/2021, 03:59 PM |
Q3 2020 | 120 | $25B | +$10.4B | -$8.32B | +$2.08B | SGEN, BGNE, INCY, ACAD, ALXN | 13F-HR | 11/16/2020, 04:00 PM |
Q2 2020 | 114 | $22.7B | +$622M | -$796M | -$174M | SGEN, INCY, BGNE, ACAD, ALXN | 13F-HR | 8/14/2020, 04:08 PM |
Q1 2020 | 110 | $16.2B | +$318M | -$145M | +$174M | SGEN, INCY, ACAD, BGNE, ALXN | 13F-HR | 5/15/2020, 04:03 PM |
Q4 2019 | 99 | $18.8B | +$689M | -$1.12B | -$433M | SGEN, INCY, BGNE, ACAD, ALXN | 13F-HR | 2/14/2020, 04:26 PM |
Q3 2019 | 109 | $14.7B | +$343M | -$273M | +$70M | SGEN, INCY, ACAD, BGNE, ALXN | 13F-HR | 11/14/2019, 04:05 PM |
Q2 2019 | 103 | $14.7B | +$308M | -$653M | -$345M | SGEN, INCY, BGNE, ALXN, ACAD | 13F-HR | 8/14/2019, 04:01 PM |
Q1 2019 | 96 | $15.6B | +$258M | -$245M | +$12.7M | SGEN, INCY, BGNE, ALXN, ACAD | 13F-HR | 5/15/2019, 04:06 PM |
Q4 2018 | 93 | $12.2B | +$526M | -$492M | +$33.9M | SGEN, INCY, BGNE, ALXN, GHDX | 13F-HR | 2/13/2019, 04:14 PM |
Q3 2018 | 97 | $15.2B | +$453M | -$605M | -$152M | SGEN, INCY, BGNE, ALXN, GHDX | 13F-HR | 11/14/2018, 03:50 PM |
Q2 2018 | 119 | $13.3B | +$1.49B | -$474M | +$1.02B | SGEN, INCY, BGNE, ALXN, BMRN | 13F-HR | 8/14/2018, 03:48 PM |
Q1 2018 | 114 | $11.8B | +$818M | -$325M | +$493M | INCY, SGEN, BGNE, ALXN, BMRN | 13F-HR | 5/15/2018, 03:47 PM |
Q4 2017 | 123 | $11.5B | +$716M | -$306M | +$410M | INCY, SGEN, ALXN, ACAD, BMRN | 13F-HR | 2/14/2018, 03:49 PM |
Q3 2017 | 121 | $12.3B | +$271M | -$98.4M | +$173M | INCY, SGEN, ALXN, ACAD, BMRN | 13F-HR | 11/14/2017, 03:45 PM |
Q2 2017 | 120 | $11.4B | +$420M | -$238M | +$182M | INCY, SGEN, ALXN, ACAD, BMRN | 13F-HR | 8/14/2017, 03:48 PM |
Q1 2017 | 119 | $12.2B | +$1.55B | -$1.27B | +$286M | INCY, SGEN, ACAD, ALXN, GHDX | 13F-HR | 5/15/2017, 04:00 PM |
Q4 2016 | 133 | $10.2B | +$302M | -$1.03B | -$728M | SGEN, INCY, ALXN, ACAD, GHDX | 13F-HR | 2/14/2017, 04:13 PM |
Q3 2016 | 134 | $11B | +$268M | -$281M | -$12.2M | SGEN, INCY, ABBV, ACAD, ALXN | 13F-HR | 11/14/2016, 05:30 PM |
Q2 2016 | 135 | $9.54B | +$85M | -$544M | -$459M | INCY, SGEN, ABBV, ACAD, ALXN | 13F-HR | 8/15/2016, 04:07 PM |
Q1 2016 | 134 | $9.48B | +$970M | -$380M | +$590M | INCY, SGEN, ALXN, ABBV, ACAD | 13F-HR | 5/16/2016, 04:12 PM |
Q4 2015 | 133 | $12.1B | +$479M | -$140M | +$340M | INCY, SGEN, ALXN, ABBV, ACAD | 13F-HR | 2/16/2016, 04:52 PM |
Q3 2015 | 133 | $10.8B | +$1.45B | -$710M | +$737M | INCY, SGEN, ALXN, ABBV, ACAD | 13F-HR | 11/16/2015, 04:07 PM |
Q2 2015 | 126 | $11.4B | +$2.52B | -$4.42B | -$1.91B | INCY, SGEN, ALXN, ABBV, ACAD | 13F-HR | 8/14/2015, 04:19 PM |
Q1 2015 | 130 | $12B | +$633M | -$871M | -$238M | PCYC, INCY, GEVA, SGEN, ACAD | 13F-HR | 5/15/2015, 04:06 PM |
Q4 2014 | 121 | $9.8B | +$882M | -$134M | +$748M | PCYC, INCY, GEVA, SGEN, AVNR | 13F-HR | 2/17/2015, 04:15 PM |
Q3 2014 | 107 | $7.83B | +$270M | -$532M | -$262M | PCYC, SGEN, GEVA, INCY, ACAD | 13F-HR | 11/14/2014, 04:51 PM |
Q2 2014 | 106 | $8.16B | +$449M | -$373M | +$75.6M | GEVA, PCYC, SGEN, INCY, ACAD | 13F-HR | 8/14/2014, 04:15 PM |
Q1 2014 | 108 | $7.87B | +$656M | -$435M | +$222M | SGEN, GEVA, PCYC, INCY, ACAD | 13F-HR | 5/15/2014, 04:10 PM |
Q4 2013 | 95 | $7.1B | $0 | $0 | PCYC, SGEN, INCY, GEVA, ACAD | 13F-HR | 2/14/2014, 04:21 PM |